Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00950859 · ClinicalTrials.gov registry record · Phase 2
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Phase 2 study of Infection, Human Immunodeficiency Virus, sponsored by ViiV Healthcare.
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
- 20
- Study locations
NCT00950859 is a Phase 2 study of Infection, Human Immunodeficiency Virus that has completed, run by ViiV Healthcare. The registered enrollment target is 51 participants, below the 145-participant average among 19 other Infection, Human Immunodeficiency Virus trials with a reported enrollment target (65% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT00950859, a Phase 2 study of Infection, Human Immunodeficiency Virus, has completed, sponsored by ViiV Healthcare.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
- 20
- Study locations
Study Summary
Integrase is an enzyme produced by HIV so that the virus can multiply in the human body. GSK1349572 is a new drug in the integrase inhibitor class that prevents the enzyme from working properly and therefore prevents the virus from multiplying. GSK1349572 has shown to be effective against viruses in a short-term monotherapy study in adults with no previous exposure to integrase inhibitors. The purpose of this study is to determine whether GSK1349572 is effective in the treatment of HIV-infected patients who no longer respond to treatment with the approved integrase inhibitor raltegravir and carry viruses with resistance to this drug. The safety and efficacy of GSK1349572 50mg once daily in combination with the background HIV drugs previously administered (unless discontinuation of a particular drug is required) will be assessed over 10 days (functional monotherapy phase), followed by the evaluation of the safety and efficacy of GSK1349572 given with a new optimised background regimen from Day 11 through at least Week 24.
Conditions Studied
Interventions
- DRUG GSK1349572 (Cohort I)
- DRUG GSK1349572 (Cohort II)
Study Locations (20)
Other
- GSK Investigational Site - Bordeaux
- GSK Investigational Site - Le Kremlin-Bicêtre
- GSK Investigational Site - Lyon
- GSK Investigational Site - Marseille
- GSK Investigational Site - Montpellier
- GSK Investigational Site - Nice
Florida
- GSK Investigational Site - Fort Lauderdale
- GSK Investigational Site - Fort Lauderdale
- GSK Investigational Site - Orlando
California
- GSK Investigational Site - Long Beach
- GSK Investigational Site - San Francisco
North Carolina
- GSK Investigational Site - Chapel Hill
- GSK Investigational Site - Charlotte
Arizona
- GSK Investigational Site - Phoenix
Colorado
- GSK Investigational Site - Denver
District of Columbia
- GSK Investigational Site - Washington D.C.
New Mexico
- GSK Investigational Site - Santa Fe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2009-08 |
| Est. Completion | 2015-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00950859
The ClinicalTrials.gov registry entry for NCT00950859 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 145-participant average among 19 other Infection, Human Immunodeficiency Virus trials with a reported enrollment target (65% lower). The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Infection, Human Immunodeficiency Virus appearing as the primary indexed condition, and to 2 interventions - of which GSK1349572 (Cohort I) is the first listed.
NCT00950859 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, Florida, California.
Frequently Asked Questions
What is clinical trial NCT00950859 about?
NCT00950859 is a clinical study titled "A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir". Integrase is an enzyme produced by HIV so that the virus can multiply in the human body. GSK1349572 is a new drug in the integrase inhibitor class that prevents the enzyme from working properly and therefore prevents the virus from multiplying. GSK1349572 has shown to be effective against viruses i...
What is the current status of trial NCT00950859?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2009-08. Estimated completion is 2015-01.
What conditions does trial NCT00950859 study?
This clinical trial studies the following conditions: Infection, Human Immunodeficiency Virus.
What interventions are being tested in trial NCT00950859?
The interventions under investigation include: GSK1349572 (Cohort I) (DRUG), GSK1349572 (Cohort II) (DRUG).
Who is sponsoring clinical trial NCT00950859?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00950859 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Infection, Human Immunodeficiency Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine
COMPLETED · Phase 2
-
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
ACTIVE NOT RECRUITING · Phase 3
-
Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction
COMPLETED · Phase 1
-
Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine
COMPLETED · Phase 1
-
A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects
COMPLETED · Phase 3
-
A Study to Assess The Relative Bioavailability of New Tablet Formulations of GSK1265744 in Healthy Adult Subjects
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.